【摘要】 目的:观察CAG方案(阿糖胞苷+阿柔比星+粒细胞集落刺激因子)治疗中高危骨髓增生异常综合征(MDS)的临床疗效及主要不良反应。方法:应用CAG方案治疗中高危MDS 17例。1个周期后评价疗效,有效者继续接受1个周期治疗,缓解后治疗采用CAG方案与常规化疗交替。结果:17例患者中,完全缓解(CR)6例,部分缓解(PR)5例,骨髓完全缓解(MCR)伴血液学进步(HI)5例,未缓解(NR)1例。有效率94.12%,完全缓解率35.30%。6例进展为急性髓系白血病(AML),中位总时间为10.5个月(6～16个月)。中位死亡时间17个月(10～22个月),1年总生存率88.24%,2年总生存率69.33%。主要的不良反应为骨髓抑制(15/17)。结论:CAG方案治疗中高危MDS安全有效,长期疗效仍需进一步观察。更多还原

【Abstract】 OBJECTIVE:To observe the efficacy and adverse events of treatment for the intermediate and high risk myelodysplastic syndrome(MDS) with CAG regimen.METHODS:Seventeen patients were included,the outcome was evaluated after 1 course of treatm ent.The responders continued to receive another course of treatment,and received CAG regimen or intensive chemotherapy altermative for post-remission therapy.RESULTS: Six cases achieved completely remission(CR),5 cases achieved partial remission(PR),5 cases achieved bone marrow completely remission(MCR) and hematologic improvement(HI),only 1 case none remission(NR).CAG regimen achieved a CR rate of 35.30% and RR rate of 94.12%.Six cases progressed to AML,and the median time was 10.5 months.The median time of death was 17 months.The overall survival rates were 88.24% at 1 year and 69.33% at 2 years.CONCLUSION: CAG regimen for middle and high risk MDS is effective.Long-term outcome needs to be observed further.更多还原